Report

The deep brain stimulation (DBS) devices market is expected to register a CAGR of nearly 12.5% during the forecast period.

The COVID-19 pandemic is expected to have a significant impact on market growth. The pandemic restrictions worsened motor and psychiatric symptoms in patients suffering from neurological disorders treated with deep brain stimulation (DBS) devices. The pandemic worsened the burden of brain disorders and surged the chronic stress related to deep brain stimulation management. According to the study published by the Neurologia Journal in August 2021, during the pandemic, the prevalence of COVID-19 in Parkinson's patients was 11.28%. However, COVID-19 in Parkinson's patients undergoing Deep Brain Stimulation (DBS) was 18.18%. Thus, the worsening of neurological disorders amongst COVID-19 patients encouraged the prominent players to develop novel DBS devices, significantly impacting the market growth. For instance, according to the article published by the Nature Journal in October 2022, the pandemic accelerated the adoption of DBS teleprogramming in countries like Hungary, present in the European region.

Furthermore, the prominent players actively assisted patients requiring DBS treatment during the pandemic. For instance, in March 2021, Abbott launched the NeuroSphere Virtual Clinic, allowing patients to connect with physicians and remotely safeguard DBS devices' proper settings and functionality. The US-FDA-approved NeuroSphere Virtual Clinic enhanced patient access to optimal treatment for patients suffering from chronic movement disorders who could not go to the healthcare clinic because of COVID-19 lockdowns. Therefore, looking at the overall scenario, the COVID-19 pandemic worsened the situation of patients suffering from neurological disorders. However, the market registered stable growth due to the increased adoption of remote solutions and is expected to witness significant growth during the forecast period.

DBS is a widely used treatment for advanced Parkinson's disease (PD), essential tremors, and dystonia. Over the past few years, in addition to the extension of its clinical applications, there has been tremendous growth in deep brain stimulation technology. The major factors driving the development of the market include the rapidly aging population, which is leading to risk and high prevalence of neurological disorders, growing demand for the devices due to the rising popularity of minimally invasive procedures, and availability of technologically advanced deep brain stimulation devices.

The rising prevalence of various neurological disorders like Epilepsy is projected to drive the market growth during the forecast period. For instance, according to the key facts published by the WHO in February 2023, approximately 50 million people worldwide have Epilepsy, making it one of the most common neurological diseases globally. As per the same source, about 80% of people with Epilepsy live in low- and middle-income countries. Furthermore, the prominent players are actively participating in the launch of advanced DBS devices in various countries worldwide, which is also burgeoning the market growth. For instance, in August 2022, Medtronic Private Limited, a subsidiary of Medtronic plc, launched the SenSight directional lead system for DBS therapy to treat movement disorders and Epilepsy in India. Similarly, in December 2022, Medtronic plc launched its DBS system, Percept PC, in South Korea to treat tremors and Parkinson's patients. Percept PC is equipped with BrainSense technology to provide electrical DBS treatment to neurological patients.

Therefore, the market is expected to grow significantly during the forecast period due to the abovementioned factors. However, risks associated with deep brain stimulation procedures and the implementation of stringent government policies are expected to hamper market growth during the forecast period.

Deep Brain Stimulation Devices Market Trends

Parkinson's disease segment is expected to hold a significant market share during the forecast period

The increasing prevalence of Parkinson's disease globally has created a higher demand for effective treatment options. DBS has emerged as a valuable therapy for managing Parkinson's symptoms and improving patients' quality of life. For instance, according to the article published by the NIH in January 2023, Parkinson's disease (PD), after Alzheimer's disease, is the second-most common neurodegenerative disorder, mainly in people aged 50 years or older. However, 5 to 10 per cent of people with PD are diagnosed before age 50, and around 500,000 Americans are diagnosed with PD yearly. Therefore, the high prevalence of PD is projected to drive the demand for advanced DBS technologies for treatment, thereby driving market growth. In addition, according to an article published by the Government of Canada in April 2022, more than 90,000 individuals aged 40 and older are currently suffering from PD in Canada. The advancements in DBS technology, such as more precise targeting and programming capabilities, have enhanced the efficacy and safety of the treatment.

Additionally, growing awareness among patients and healthcare professionals about the benefits of DBS for Parkinson's disease has contributed to market growth. Furthermore, ongoing research and development activities, product launches, partnerships to improve DBS technologies, and expanding indications have propelled the market forward. For instance, in August 2022, Aster Medcity Hospital and Medtronic plc partnered to build a comprehensive and advanced DBS program for Parkinson's patients in India. The program aims to improve PD management by allowing surgeons to make more accurate DBS therapy treatment decisions.

Hence, due to the abovementioned factors, the Parkinson's Disease segment will likely grow significantly during the forecast period.

North America is expected to hold a significant share in the market and is expected to do the same during the forecast period

The geographical analysis of the deep brain stimulation devices market shows that North America holds a significant market share in the global market. This is due to the rising prevalence of various neurological disorders in the region, the presence of prominent players, and the increasing number of product launches. For instance, as per the data updated by the CDC in May 2022, approximately 3 million adults in the United States are currently having Epilepsy. In addition, as per the data updated by the American Psychiatric Association in October 2022, Obsessive Compulsive Disorder (OCD) affects around 2-3% of people in the United States annually. Therefore, the region's high prevalence of various neurological disorders is projected to create a high demand for advanced DBS devices, augmenting regional market growth. In addition, the presence of different prominent players in the region and their active participation in launching advanced DBS devices is also driving the regional market growth. For instance, in July 2022, Abbott received breakthrough device designation from the US FDA for using its DBS system in treatment-resistant depression in the United States. In addition, in April 2022, Boston Scientific Corporation received the US FDA approval for its latest image-guided programming software, Vercise Neural Navigator, with STIMVIEW XT. The DBS device visualizes both lead placement and stimulation modeling of the brain anatomy of patients living with PD or essential tremors.

Thus, the regional market is expected to witness significant growth during the forecast period due to the abovementioned factors.

Deep Brain Stimulation Devices Industry Overview

The deep brain stimulation devices market is consolidated, owing to the presence of a few major market players. Some market players are Abbott Laboratories, Beijing Pinchi Medical Equipment Co., Ltd., Boston Scientific Corporation, Fisher Wallace, Functional Neuromodulation Ltd., Medtronic PLC, NeuroPace Inc., and Renishaw PLC.

Additional Benefits:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support